newsfilter
← Latest News
Business Wire·

Iambic Announces Pricing of Initial Public Offering

  • Iambic Therapeutics, Inc. priced its initial public offering of 9,375,000 shares at $16.00 per share.
  • The gross proceeds from the offering are expected to be $150.0 million before deducting underwriting discounts, commissions, and other expenses.
  • Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the offering price.
  • Iambic common stock is scheduled to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol "IAM."
  • The offering is expected to close on October 16, 2026, subject to customary closing conditions.
  • J.P. Morgan, Jefferies, BofA Securities, and Citigroup are serving as joint book-running managers for the offering.
  • The registration statement became effective on October 14, 2026, with the final prospectus available via the SEC or the lead underwriters.
  • Iambic utilizes a platform integrating proprietary AI with automated chemistry and biology experimentation to advance drug discovery.
  • The company's lead AI technologies include Enchant and NeuralPLexer for multimodal endpoint prediction.
  • Iambic advanced its novel drug candidate IAM1363 to clinical trials in approximately two years.